Idag den 4 april 2022 publicerade Abelco bolagets kvartalsredogörelse för Q1-22 och givet att vår se...
Under förra veckan kommunicerade Transfer att det helägda dotterbolaget CSG dels tecknat ett treårig...
Redeye provides a short comment on today’s news regarding CEO Karin Fischer’s decision to leave.
Fortsatt utrullning av ramavtal borde ge stöd till försäljningen Trots att tillväxttakten i slutet a...
Redeye is encouraged by Fluoguide communicating excellent safety and promising early signs of effica...
Soltech har haft en intensiv period med nya ordrar och flera förvärv.
We give a short comment on the additional information from the phase II trial with Rabeximod in Covi...
Redeye initiates coverage of Ultimovacs, a Nordic biotech company developing therapeutic cancer vacc...
Redeye states that Catella is continuing its strategic actions to streamline operations and focus on...
CirChem publicerade igår den 31 mars 2021 sin delårsrapport för fjärde kvartalet 2021.
Redeye's view continues to be that BioArctic's drug candidate lecanemab has a high likelihood of app...
Redeye comments on Invisio’s announcement of three large orders which confirms our view of strong gr...
Redeye comments on Flexions transformative acquisition of Audiencly, a leading influencer marketing ...
Rapportkommentar Diamyd släppte under onsdagen sin rapport för det andra kvartalet i det brutna räke...
Administer’s H2 figures were well in line with our expectations, with revenue of EUR 22.
Redeye initiates coverage of Sedana Medical, a medtech/pharma company challenging the standard of ca...
Fjärde kvartalet 2021 bjöd på väsentligt lägre intäkter än våra prognoser.
Redeye comments on Fluoguide’s Q4 report, following a relatively calm couple of months on the news f...
Redeye comments on today's CEO announcement
Annexin Pharmaceuticals held a Strategy Update on the 30th of March.
